Ex-Meditech CEO to head WA firm Acuron
Monday, 29 November, 2004
Three months after being forced to step down as CEO of Melbourne biotech Meditech (ASX:MTR) after a shareholder stoush, expat South African Chris Carter has been appointed CEO of Western Australian minerals-explorer-turned-biotech Acuron (ASX:AVP).
Acuron's two wholly owned subsidiaries, Vacutex and Pro-Tex, manufacture and distribute a range of advanced wound care products. The company's flagship product -- capillary action dressing Vacutex -- has been approved by the TGA and the UK's National Health Scheme, and is also distributed in the Middle East and parts of South-East Asia. Acuron is in the process of submitting for approval from the US Food and Drug Administration (FDA).
Carter will take over from George Cameron-Dow as Acuron's managing director, and from Johann Fourie as CEO of both Vacutex and Pro-Tex. Both Cameron-Dow and Fourie will move to non-executive roles.
"We are very pleased to announce Chris's appointment as we accelerate the global roll-out of Acuron's advanced wound care product range." said Acuron chairman, Patrick O'Connor in a statement. "Chris has a strong track record in developing healthcare businesses and in securing the support of institutional investors."
New route into cells found for gene therapy viruses
Scientists have identified a previously unknown gateway into human cells — a receptor...
Link between oestrogen and heart health found in women
Scientists found that oestrogen helps increase the ANXA1 protein, and when ANXA1 is missing, the...
Frequent nightmares accelerate aging, increase risk of death
Nghtmares independently predict faster biological aging and earlier mortality — even after...
